Heart failure & cardiomyopathies
Efficacy of Ambulatory Intravenous Diuresis for Chronic Heart Failure Patients: Insights from the DEA-HF Trial
Authors' conclusion
In patients with congestion-refractory HF, an ambulatory strategy utilizing high-intensity weekly IV diuretic therapy achieved effective decongestion without major safety concerns.
Study context
- Population
- Chronic heart failure (HF) patients with congestion despite guideline-directed medical therapy; 40% female, mean age 72 ± 9 yearscrossover
- Participants
- 42 patients
- Comparison
- Before vs after three weekly ambulatory high-intensity intravenous (IV) diuretic treatments (regimens pooled)
- Primary endpoint
- Total sodium excretion following each diuretic regimen
Methodological detailsprospective, cross-over, pooled analysis of all regimens
- Prospective
- Cross-over
- Pooled analysis of all regimens
Primary result
As reported in the abstract
Body weight · after three consecutive weekly treatments
P = 0.0005
Further findings
Congestion score, NT-proBNP, lung ultrasound B-line count · after three consecutive weekly treatments
- Significant decrease in congestion score, NT-proBNP and lung ultrasound B-line count
Safety
Serum creatinine and AKI · after 3 consecutive weekly treatments
- Serum creatinine mildly but significantly increased from 1.81 mg/dL (95% CI: 1.62-2.01) to 2.01 mg/dL (95% CI: 1.81-2.21)
- P < 0.001
- Hospitalisations due to AKI
- 0
- All regimens pooled
Original publication
Efficacy of Ambulatory Intravenous Diuresis for Chronic Heart Failure Patients: Insights from the DEA-HF Trial. ESC Heart Fail. Published 15 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →